SAN FRANCISCO, Jan. 15, 2014 (GLOBE NEWSWIRE) -- CollabRx, Inc. (Nasdaq:CLRX), a leading data analytics company, today announced that its newest Therapy Finder for breast cancer patients will be made available in connection with the Cynvenio ClearID™ Breast Cancer genomic blood test. This announcement extends the scope of a previously disclosed multi-year agreement which announced the pairing of the CollabRx Genetic Variant Annotation (GVA) Service™ with tumor mutation profiling from whole blood provided by Cynvenio.
Patients of physicians who order the Cynvenio ClearID™ Breast Cancer genomic blood test will receive an annual subscription to a customized version of the CollabRx Therapy Finder™ app for breast cancer. The ClearID test supports the proactive monitoring of breast cancer survivors at high risk of recurrence, such as triple-negative patients (ER-, PR-, HER2-). CollabRx's breast cancer Therapy Finder app is a web-based decision support tool that enables patients (and their physicians) to take into account the molecular aspects of a metastatic breast cancer tumor when determining a treatment plan. The Therapy Finder provides for a dynamic user environment to navigate and understand both the current standard of care as well as cutting edge experimental therapy options with the goal of enabling patients to receive the best possible care. The subscription will include access to news and information to provide patient oriented educational material on advances in breast cancer medical and scientific research, risk factors for recurrence, monitoring, and early detection. The breast cancer Therapy Finder is kept dynamically up-to-date and curated by CollabRx medical and scientific personnel with the support of an editorial board composed of independent breast cancer clinical experts. The Therapy Finder for breast cancer is the most recent electronic decision support app released by CollabRx, is first such app developed specifically for a patient user, and complements existing Therapy Finders for lung cancer, colorectal cancer, and melanoma.
"This collaboration will provide breast cancer patients, survivors and their families with two powerful tools in one test," said André de Fusco, CEO of Cynvenio. "The ClearID Breast Cancer test offers genomic insights from a standard blood draw analyzed by next gen sequencing. By pairing ClearID with the CollabRx Therapy Finder we can now take into account an individual patient's molecular (tumor) data when offering the latest insights into breast cancer treatments. This is a milestone in our efforts to develop a new standard for individualized breast cancer monitoring."
"The CollabRx Therapy Finder for breast cancer provides patients with an up-to-date and easily accessible tool to navigate therapy considerations that incorporate molecular data and also receive curated news that pertains to their disease," said Thomas Mika, Chairman, President & CEO of CollabRx. "We are excited to collaborate with Cynvenio on its introduction with the goal of providing metastatic breast cancer patients with an easy to use tool to aid in treatment planning by contexualizing the state of scientific and medical research backed by sound science."
The partnership with Cynvenio represents another proof point in CollabRx's strategy to commercialize multiple newly developed products and services in 2014. This new commercial development attests to the growing adoption of CollabRx technology and interpretive analytics in top-tier laboratories worldwide as a standard aspect of interpretive medical informatics solutions in cancer and other diseases.
CollabRx, Inc. (Nasdaq:CLRX) is a recognized leader in cloud-based expert systems to inform healthcare decision-making. CollabRx uses information technology to aggregate and contextualize the world's knowledge on genomics-based medicine with specific insights from the nation's top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at http://www.collabrx.com.
Cynvenio is a cancer diagnostics company focused on transforming cancer treatment and management through the molecular analysis of tumor biomarkers in the bloodstream. This expertise has resulted in two distinct product offerings: ClearID Breast Cancer monitoring program and LiquidBiopsy®. ClearID Breast Cancer, designed for use by patients and their physicians, is a cancer detection and monitoring program that assesses 50 oncogenes for more than 4,500 genetic mutations using next-generation sequencing. This test and real-time molecular analysis provide actionable information that can inform treatment considerations and help improve treatment outcomes. LiquidBiopsy is designed for industry and academic researchers to identify the presence of tumor-cell genetic mutations in whole blood. Founded in 2008, Cynvenio is headquartered in Westlake Village, Calif. (Los Angeles). For more information visit http://www.cynvenio.com.
LiquidBiopsy® is a registered trademark of Cynvenio Biosystems, Inc.
CollabRx Safe Harbor Statement
This press release includes forward-looking statements about CollabRx's anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and CollabRx's plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by CollabRx with the Securities and Exchange Commission. CollabRx undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
CONTACT: CollabRx Contacts: Gavin J. Gordon, MBA, PhD Vice President, Business Development & Strategic Alliances CollabRx, Inc. (415) 248-5350 firstname.lastname@example.org or James Carbonara Hayden IR 646-755-7412 James@haydenir.com Cynvenio Contact: Heidi Brown Cynvenio Biosystems, Inc. 805-777-0017 x703 email@example.com